GlaxoSmithKline Pharmaceuticals Limited
GLAXO
Classement en actions
#3670
GlaxoSmithKline Pharmaceuticals Limited, an India-based healthcare enterprise,... GlaxoSmithKline Pharmaceuticals Limited, an India-based healthcare enterprise, engages in the research, development, production, and global distribution of pharmaceutical drugs and vaccines. Its extensive product range encompasses both prescription and over-the-counter medications addressing diverse therapeutic areas such as anti-infectives, respiratory ailments, dermatology, nutritional deficiencies, gastrointestinal issues, and rare conditions. The company additionally provides consumer healthcare solutions. Prominent brands within its portfolio include Augmentin, Calpol, Ceftum, Eltroxin, Neosporin, Betnovate, Infanrix Hexa, Synflorix, and Boostrix, among numerous others. Founded in 1924 and headquartered in Mumbai, India, the company adopted its current name in 2001, having previously operated as SmithKline Beecham Pharmaceuticals India Ltd.
Prix de l'action
$27.08
Capitalisation boursière
$4.59B
Changement (1 jour)
-1.68%
Changement (1 an)
-13.61%
Pays
IN
Échange GlaxoSmithKline Pharmaceuticals Limited (GLAXO)
Catégorie
Healthcare
Ratio P/B pour GlaxoSmithKline Pharmaceuticals Limited (GLAXO)
Ratio P/B au October 2026 TTM : 18.70
Selon les derniers rapports financiers et le cours de l'action de GlaxoSmithKline Pharmaceuticals Limited, le ratio cours/valeur comptable actuel (TTM) est 18.70. À la fin de 2024, le ratio P/B était de 18.93.
Historique du ratio P/B pour GlaxoSmithKline Pharmaceuticals Limited de 2004 à 2026
Ratio P/B à la fin de chaque année
| Année | Ratio P/B | Changez |
|---|---|---|
| 2026 (TTM) | 18.70 | -23.00% |
| 2025 | 24.29 | 28.30% |
| 2024 | 18.93 | 46.87% |
| 2023 | 12.89 | 21.54% |
| 2022 | 10.60 | -35.77% |
| 2021 | 16.51 | 41.12% |
| 2020 | 11.70 | 13.72% |
| 2019 | 10.29 | 18.79% |
| 2018 | 8.66 | -25.23% |
| 2017 | 11.58 | -39.20% |
| 2016 | 19.05 | 60.47% |
| 2015 | 11.87 | -7.01% |
| 2013 | 12.77 | 39.51% |
| 2012 | 9.15 | 7.51% |
| 2011 | 8.51 | -16.10% |
| 2010 | 10.15 | 32.71% |
| 2009 | 7.64 | 23.58% |
| 2008 | 6.19 | -1.82% |
| 2007 | 6.30 | -22.76% |
| 2006 | 8.16 | -19.22% |
| 2005 | 10.10 | 38.74% |
| 2004 | 7.28 | 0.00% |
Ratio P/B pour des entreprises similaires ou concurrentes
| Entreprise | Ratio P/B | Différence de Ratio P/B | Pays |
|---|---|---|---|
| 31.9092 | 70.60% |
US
|
|
| 7.3138 | -60.90% |
US
|
|
| -84.6033 | -552.32% |
US
|
|
| 8.6873 | -53.56% |
US
|
|
| 8.4776 | -54.68% |
CH
|
